Back

Impact of lipoprotein(a) levels on atherosclerotic cardiovascular disease outcomes in women

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Prediction and prognosis of coronary artery disease (2) Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ademola Ajibade

University of Iowa Hospitals and Clinics, Iowa City (United States of America)

5 More presentations in this session

Presentation thumbnail
Comparison of Cox proportional hazards models and random survival forests for long-term cardiovascular risk prediction incorporating coronary artery calcium score
Doctor G. Bettencourt Abreu (Funchal, PT)
Abstract
Presentation thumbnail
Circadian syndrome is inversely associated with lung function and cardiorespiratory fitness in the general population
Miss N. Schmidt (Greifswald, DE)
Abstract
Presentation thumbnail
Impact of mandatory cardiovascular risk assessment on risk factor control and prescribing patterns in a tertiary cardiovascular centre
Miss A. Palikuca (Novi Sad, RS)
Abstract
Presentation thumbnail
From benign to prognostic: ectopy burden predicts long-term cardiovascular events
Doctor A. Moses (Ramat Gan, IL)
Abstract
Presentation thumbnail
Prognostic significance of the hemoglobin–albumin–lymphocyte–platelet (HALP) score in rheumatic mitral stenosis: a long-term cohort study
Doctor K. Ahmet Ferhat (Van, TR)
Abstract

Access the full session

Session thumbnail
Prediction and prognosis of coronary artery disease (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Lipid profile risk in menopausal women with no significant increase in lipoprotein(a)
31 August 2025
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
6 November 2025
thumbnail
Congress Presentation
Risk factors for cardiac death in women with coronary artery disease
1 September 2025
thumbnail
Congress Presentation
The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe
28 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources